Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients

Clinical Colorectal Cancer

Volumn 15, Issue 3, 2016, Pages 257-263

  Sun, Julia ^a   Ilich, Alastair I ^a   Kim, Christina A ^a   Chu, Michael P ^a   Wong, Grace G ^a   Ghosh, Sunita ^a   Danilak, Melanie ^a   Mulder, Karen E ^a   Spratlin, Jennifer L ^a   Chambers, Carole R ^b   Sawyer, Michael B ^a  

^a CROSS CANCER INSTITUTE   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Adjuvant chemotherapy; Dose modification; pH dependent solubility; Pharmacokinetics; Toxicity

Indexed keywords

CAPECITABINE; LAPATINIB; OXALIPLATIN; PROTON PUMP INHIBITOR; ANTINEOPLASTIC AGENT;

AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SOLUBILITY; EARLY CANCER; ESOPHAGUS CANCER; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL RATE; THERAPY DELAY; TREATMENT OUTCOME; ADULT; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAPECITABINE; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 84955285606     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2015.12.008     Document Type: Conference Paper

References (28)

1. 1 Reigner, B., Blesch, K., Weidekamm, E., Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40 (2001), 85–104.
2. 2 Koukourakis, G.V., Kouloulias, V., Koukourakis, M.J., Zacharias, G.A., Zabatis, H., Kouvaris, J., Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules 13 (2008), 1897–1922.
3. 3 Borner, M.M., Schoffski, P., de Wit, R., et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38 (2002), 349–358.
4. 4 Liu, G., Franssen, E., Fitch, M.I., Warner, E., Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15 (1997), 110–115.
5. 5 Twelves, C., Boyer, M., Findlay, M., et al. Capecitabine (xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 37 (2001), 597–604.
6. 6 McLeod, H.L., Evans, W.E., Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res 5 (1999), 2669–2671.
7. 7 Budha, N.R., Frymoyer, A., Smelick, G.S., et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the achilles heel of targeted therapy?. Clin Pharmacol Ther 92 (2012), 203–213.
8. 8 Rotermann, M., Sanmartin, C., Hennessy, D., Arthur, M., Prescription medication use by Canadians aged 6 to 79. Health Rep 25 (2014), 3–9.
9. 9 Smelick, G.S., Heffron, T.P., Chu, L., et al. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm 10 (2013), 4055–4062.
10. 10 Van Cutsem, E., Verslype, C., Tejpar, S., Oral capecitabine: bridging the Atlantic divide in colon cancer treatment. Semin Oncol 32 (2005), 43–51.
11. 11 Scheithauer, W., McKendrick, J., Begbie, S., et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14 (2003), 1735–1743.
12. 12 Ha, V.H., Ngo, M., Chu, M.P., Ghosh, S., Sawyer, M.B., Chambers, C.R., Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?. J Oncol Pharm Pract 21 (2015), 194–200.
13. 13 Chu, M.P., Ghosh, S., Chambers, C.R., et al. Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer 16 (2015), 33–39.
14. 14 Hecht, J.R., Bang, Y., Qin, S., et al. Lapatinib in combination with capecitabine plus oxaliplatin in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: the TRIO-013/LOGiC trial. J Clin Oncol, 31(Suppl), 2013 (Abstract LBA4001). 2013 ASCO Annual Meeting.
15. 15 Chu, M.P., Hecht, J.R., Slamon, D.J., et al. Proton pump inhibitors may impair capecitabine efficacy in advanced gastroesophageal cancer - results from TRIO-013/LOGiC trial. Ann Oncol 25:Suppl 4 (2014), iv210–iv253.
16. 16 Hofheinz, R.D., Heinemann, V., von Weikersthal, L.F., et al. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer 107 (2012), 1678–1683.
17. 17 Stintzing, S., Fischer von Weikersthal, L., Vehling-Kaiser, U., et al. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer 105 (2011), 206–211.
18. 18 Twelves, C., Scheithauer, W., McKendrick, J., et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 23 (2012), 1190–1197.
19. 19 Reigner, B., Verweij, J., Dirix, L., et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4 (1998), 941–948.
20. 20 Reigner, B., Clive, S., Cassidy, J., et al. Influence of the antacid maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol 43 (1999), 309–315.
21. 21 Maton, P.N., Burton, M.E., Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 57 (1999), 855–870.
22. 22 Sontag, S.J., The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am 19 (1990), 683–712.
23. 23 Rohss, K., Lind, T., Wilder-Smith, C., Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 60 (2004), 531–539.
24. 24 Mullin, J.M., Gabello, M., Murray, L.J., et al. Proton pump inhibitors: actions and reactions. Drug Discov Today 14 (2009), 647–660.
25. 25 Shin, J.M., Sachs, G., Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 10 (2008), 528–534.
26. 26 Chiba, N., De Gara, C.J., Wilkinson, J.M., Hunt, R.H., Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112 (1997), 1798–1810.
27. 27 Sigterman, K.E., van Pinxteren, B., Bonis, P.A., Lau, J., Numans, M.E., Short-term treatment with proton pump inhibitors, H2-receptor antagonists, and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev, 5, 2013, CD002095.
28. 28 U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Tarceva NDA 21–743/S000 clinical pharmacology and biopharmaceutics review [Web site]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva_biopharmr.PDF. Updated November 18, 2004. Accessed March 16, 2015.